Department of Pediatrics, Duke University Medical Center, Durham, NC, USA.
Vaccine. 2010 Jun 17;28(27):4376-83. doi: 10.1016/j.vaccine.2010.04.058. Epub 2010 May 4.
We assessed the effect of age on immunogenicity to trivalent inactivated influenza vaccine (TIV) by comparing the immune responses to influenza vaccine antigens among three age cohorts of vaccine-naïve children aged 6-11 months, 12-17 months, and 18-23 months. In children 6-23 months of age, antibody responses to TIV appear to increase with increasing age. Despite this finding, TIV was immunogenic even in the youngest age group evaluated, further establishing its value as a tool to protect young children from influenza. The role of age should be considered when assessing improved vaccines to enhance TIV immunogenicity and effectiveness in younger children.
我们通过比较三个年龄组（6-11 个月、12-17 个月和 18-23 个月）的儿童对流感疫苗抗原的免疫反应，评估了年龄对三价灭活流感疫苗（TIV）免疫原性的影响。在 6-23 个月龄的儿童中，TIV 的抗体反应似乎随年龄增长而增加。尽管有这一发现，但 TIV 在评估的最小组年龄中仍具有免疫原性，进一步证实了其作为保护幼儿免受流感侵害的工具的价值。在评估增强 TIV 在幼儿中的免疫原性和有效性的改进疫苗时，应考虑年龄的作用。
